Geetha Ramaswamy, MD
Interventional Cardiology · Flower Mound, TXNPI 1841216595
Payments from drug & device makers
Across 605 payments — averaging $24.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$3K
- Boston Scientific$2K
- Edwards Lifesciences$2K
- Abbott$2K
- E.r. Squibb & Sons, L.L.C.$767
- Novartis$619
- plus $3K from 32 others
Across 1 payment — averaging $2000.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$2K
What the payments were for
- Travel & lodging$3,13622%
- Food & beverage$11,37778%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 189 | $3,393 |
| Boston Scientific | 44 | $2,410 |
| Edwards Lifesciences | 23 | $2,258 |
| Abbott | 30 | $1,720 |
| E.r. Squibb & Sons, L.L.C. | 70 | $767 |
| Novartis | 36 | $619 |
| Abiomed | 9 | $560 |
| Pfizer | 43 | $488 |
| Johnson & Johnson | 69 | $439 |
| Amgen | 20 | $258 |
| Philips North America LLC | 8 | $208 |
| Merck | 11 | $199 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $147 |
| Boehringer Ingelheim | 6 | $113 |
| Biotronik Inc. | 1 | $99 |
| Bayer | 1 | $94 |
| Alnylam Pharmaceuticals Inc. | 4 | $86 |
| Inspire Medical Systems, Inc. | 4 | $83 |
| Terumo Medical Corporation | 3 | $60 |
| Sanofi-aventis U.S. LLC | 3 | $59 |
| AstraZeneca | 3 | $51 |
| Shockwave Medical, Inc | 2 | $46 |
| Bard Peripheral Vascular, Inc. | 1 | $43 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $42 |
| Teleflex LLC | 2 | $40 |
| Irhythm Technologies, Inc. | 2 | $31 |
| Bardy Diagnostics, Inc. | 2 | $24 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $23 |
| Inari Medical, Inc. | 1 | $22 |
| Agepha Pharma FZ LLC | 1 | $21 |
| Baxter Healthcare | 1 | $17 |
| Scpharmaceuticals Inc. | 1 | $16 |
| Amarin Pharma, Inc. | 1 | $16 |
| Cardiovascular Systems Inc. | 1 | $15 |
| Heartflow, Inc. | 1 | $15 |
| Chiesi USA, Inc. | 1 | $14 |
| Portola Pharmaceuticals, LLC | 1 | $14 |
| Astellas Pharma US Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,522 in reported general payments places this provider in the 55th percentile of 686 interventional cardiology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 364 | $371,720 |
| JardianceEmpagliflozin | 45 | $66,710 |
| EntrestoSacubitril/Valsartan | 37 | $46,285 |
| XareltoRivaroxaban | 34 | $38,079 |
| BrilintaTicagrelor | 42 | $37,676 |
| Repatha SureclickEvolocumab | 27 | $17,126 |
| Metoprolol Succinate | 232 | $3,219 |
| Rosuvastatin Calcium | 225 | $2,506 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 80 | $2,304 |
| Potassium Chloride | 82 | $2,218 |
| ClopidogrelClopidogrel Bisulfate | 187 | $2,151 |
| Losartan Potassium | 154 | $1,390 |
| Amlodipine Besylate | 218 | $1,320 |
| Olmesartan Medoxomil | 27 | $1,236 |
| Atorvastatin Calcium | 110 | $1,110 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $488 | $371,720364 claims |
| Boehringer IngelheimJardiance | $113 | $66,71045 claims |
| NovartisEntresto | $619 | $46,28537 claims |
| Johnson & JohnsonXarelto | $439 | $38,07934 claims |
| AstraZenecaBrilinta | $51 | $37,67642 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 686 interventional cardiology providers in Texas.
Other interventional cardiology in Flower Mound
- Robert StolerDallas$8.2M
- James ChoiDallas$5.2M
- Srinivasa PotluriPlano$5.1M
- Neal KleimanHouston$4.8M
- Juan GranadaHouston$4.3M
- Ira LieberKingwood$3.3M
- Cara Ann EastDallas$3M
- Abhijeet DhobleHouston$2.7M
- Jeffrey CarrTyler$2.7M
- M Asad KarimMcKinney$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.